Tankyrase inhibitors enhance the degradation of β-catenin and inhibit cell proliferation in CRC cell lines that harbour APC mutations (Schatoff et al., 2019; Jang et al., 2020). The gene discussed is APC; the disease is colorectal carcinoma.